Nkarta ( (NKTX) ) has shared an update.
On November 9, 2026, Nkarta announced initial clinical data from its Ntrust program, presented at ACR Convergence 2026. At the 4 billion-cell dose, five of six myositis patients with at least three months of follow-up achieved moderate or major responses, while six of seven systemic sclerosis patients achieved rCRISS-25 responses or greater; five achieved rCRISS-50 responses or greater, alongside substantial skin-score improvements.
Integrated safety data from 40 patients across five autoimmune indications showed no deaths, treatment discontinuations due to adverse events, cytokine release syndrome, neurotoxicity, hemophagocytic lymphohistiocytosis-like syndrome or graft-versus-host disease. Adverse events were mainly transient hematologic effects attributed to preconditioning, while the company characterized the findings as preliminary and based on small patient numbers with limited follow-up.
The most recent analyst rating on (NKTX) stock is a Buy
with a $12.00 price target.
To see the full list of analyst forecasts on Nkarta stock,
see the NKTX Stock Forecast page.
Spark’s Take on NKTX Stock
According to Spark, TipRanks’ AI Analyst, NKTX is a Neutral.
The score is weighed down primarily by weak financial performance (no revenue, large and worsening TTM losses, and significant negative free cash flow) and a clear bearish technical trend (price below all key moving averages with negative MACD). Valuation provides limited support because the company is unprofitable (negative P/E) and has no dividend yield data.
To see Spark’s full report on NKTX stock,
click here.
More about Nkarta
Nkarta, Inc. is a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies for autoimmune diseases. Its NKX019 candidate is an allogeneic, off-the-shelf, CD19-directed CAR NK cell therapy being evaluated for autoimmune conditions.
Average Trading Volume: 798,039
Technical Sentiment Signal: Sell
Current Market Cap: $124M
Find detailed analytics on NKTX stock on TipRanks’ Stock Analysis page.